SCHEMBL27660967

SCHEMBL27660967

CCCCNc1cccnc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
UTS2R Q9UKP6 5/20 0.46
TLR8 Q9NR97 3/20 0.46
TLR7 Q9NYK1 1/20 0.46
NR4A2 P43354 1/20 0.42
KDM6B O15054 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
PDE5A O76074 1/20 0.40
CDC7 O00311 1/20 0.39
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
PIM1 P11309 1/20 0.39
PRKACA P17612 1/20 0.39
CDK2 P24941 1/20 0.39
GSK3B P49841 1/20 0.39
HIPK2 Q9H2X6 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
MAPK8 P45983 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8510590 0.93 L3MBTL1 (0.45) NPC1UTS2RTLR8TLR7SMN1; SMN2
SCHEMBL8510998 0.89 PDE5A (0.48) NPC1KDM6BKDM4CPDE5AHTT
SCHEMBL8670176 0.87 HTT (0.50) PDE5AHTTHSP90AA1HSP90AB1MAPT
SCHEMBL31613110 0.87 HTT (0.50) PDE5AHTTHSP90AA1HSP90AB1MAPT
SCHEMBL3968831 0.84 PDE4B (0.43) PDE5AHTTHSP90AA1HSP90AB1MAPT
SCHEMBL8508286 0.81 GRM5 (0.51) HTTCYP3A4
SCHEMBL19897481 0.81 BACE1 (0.54) NPC1UTS2RTLR8TLR7KDM6B
SCHEMBL1974279 0.81 KDM4E (0.47) NPC1UTS2RTLR8TLR7NR4A2
SCHEMBL30692781 0.81 NPC1 (0.47) NPC1UTS2RTLR8TLR7NR4A2
SCHEMBL7515463 0.80 MAPT (0.44) HTTMAPTKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1930144-A 3-'4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases BOEHRINGER INGELHEIM PHARMA (US) 2007-03-14 CN disclosed